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Immunotherapy for Unresectable Stage III Non–Small-Cell 
Lung Cancer
Naiyer A. Rizvi, M.D., and Solange Peters, M.D., Ph.D.
In this issue of the Journal, Antonia and col-
leagues report the results of the phase 3 PACIFIC 
study, which evaluated the role of immune check-
point blockade in locally advanced, unresectable, 
stage III non–small-cell lung cancer (NSCLC).1 
Eligible patients had disease that had not yet 
progressed after they had received at least two 
cycles of platinum-based chemotherapy concur-
rent with radiotherapy (chemoradiotherapy) at a 
dose of 54 to 66 Gy. A total of 713 patients were 
randomly assigned, in a 2:1 ratio, to receive an 
anti–programmed death ligand 1 (anti–PD-L1) 
antibody, durvalumab, at a dose of 10 mg per 
kilogram of body weight or placebo every 2 weeks 
for up to 12 months.
Worldwide, approximately 500,000 patients re-
ceive a diagnosis of unresectable stage III NSCLC 
every year; this number constitutes approximately 
one third of all patients with NSCLC. Stage III 
NSCLC includes either locally advanced primary 
tumors with infiltration of vital mediastinal or-
gans or involvement of locoregional mediastinal 
lymph nodes. Over the past decade, chemoradio-
therapy has remained the standard of care for 
stage III NSCLC. Currently, only 15% of patients 
are alive 5 years after chemoradiotherapy, and 
this percentage remains largely unchanged de-
spite multiple phase 3, randomized trials inte-
grating surgery; increased doses of radiation or 
consolidation of radiotherapy with chemotherapy; 
biologic agents; or vaccine treatment.2,3
In the study reported by Antonia et al., a pre-
planned interim analysis showed that the copri-
mary end point of median progression-free sur-
vival was 16.8 months in the durvalumab group 
versus 5.6 months in the placebo group, corre-
sponding to a hazard ratio for disease progres-
sion or death of 0.52 (95% confidence interval, 
0.42 to 0.65). The response rate was higher in the 
durvalumab group than in the placebo group. 
The robustness and consistency of the results 
were supported by multiple prespecified sensitiv-
ity analyses. Benefit was observed independently 
of NSCLC disease stage (IIIA or IIIB), histologic 
type, or geographic distribution.
In a comparable patient population in the 
RTOG 0617 trial, progression-free survival among 
patients in the control chemoradiotherapy group 
was 11.8 months, which was longer than that 
observed in the placebo group of the PACIFIC 
study (5.6 months).3 However, progression-free 
survival in the RTOG 0617 trial was calculated 
from the initiation of chemoradiotherapy. In the 
Stimulating Targeted Antigenic Response to 
NSCLC (START) trial, in which randomization 
occurred after chemoradiotherapy, the progres-
sion-free survival among patients in the control 
group was 8.4 months.4 In the study by Antonia 
et al., randomization occurred after patients had 
completed chemoradiotherapy and could take 
place up to 42 days after the end of chemoradio-
therapy, allowing for resolution of toxic effects 
associated with chemoradiotherapy. Factoring in 
these variables, results in the control group of 
the PACIFIC study were not inconsistent with 
data from previous phase 3 trials.
Overall survival continues to be the standard 
for outcomes in the treatment of locally advanced 
NSCLC. Nevertheless, in the PACIFIC study, 
progression-free survival was almost 17 months in 
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the durvalumab group, which was almost 1 year 
longer than progression-free survival in the pla-
cebo group; this duration is unprecedented in 
stage III NSCLC. Additional relevant surrogate 
end points included the development of new dis-
tant lesions that were more frequently observed 
in the placebo group than in the durvalumab 
group. Most notably, brain metastasis developed 
in twice as many patients in the placebo group 
as in the durvalumab group (11.0% vs. 5.5%). 
Furthermore, progression-free survival has been 
found to correlate with overall survival in previ-
ous chemoradiotherapy studies.5 The overall sur-
vival benefit frequently exceeds the progression-
free survival benefit in other studies of immune 
checkpoint inhibitors that involve patients with 
advanced-stage NSCLC.6 Although the overall sur-
vival data in this study have yet to mature, the 
clinically meaningful difference in progression-
free survival merits consideration of durvalumab 
as a new standard of care in this patient popu-
lation.
Given the potential for radiotherapy to in-
crease the likelihood of anti–PD-L1–mediated 
pneumonitis, uncertainty existed as to the risk 
of the use of durvalumab. Treatment-related ad-
verse events occurred in 67.8% of patients in the 
durvalumab group, as compared with 53.4% in 
the placebo group. The rate of immune-mediated 
adverse events was 24.2% with durvalumab and 
8.1% with placebo. Treatment was discontinued 
because of pneumonitis in 6.3% of patients who 
received durvalumab and 4.3% who received 
placebo. Overall, a slight increase in toxic effects 
was noted in the durvalumab group, but the 
rates of severe immune-related adverse events 
and of pneumonitis, in particular, were not 
meaningfully different.
Can these results with durvalumab be extrapo-
lated to patients with resectable stage III dis-
ease? In the phase 3 Intergroup 0139 trial, the 
addition of surgery to chemoradiotherapy was 
not associated with a survival advantage.7 Never-
theless, on the basis of retrospective subgroup 
analyses, standard treatment for “selected” pa-
tients with stage IIIA N2 disease (patients with 
a single nodal station who are candidates for 
lobectomy and have clearing of mediastinal 
nodes with induction therapy) involves consider-
ing resection after neoadjuvant chemotherapy, 
although this varies according to geographic 
location. The data from the PACIFIC study may 
end the debate about the role of surgery in pa-
tients with stage III NSCLC, with durvalumab 
after chemoradiotherapy redefining best practice 
for all patients with stage III NSCLC. Of course, 
this notion will need to be tested prospectively.
Benefit in the PACIFIC study was observed in 
patients with nonsquamous and squamous tu-
mor histologic types as well as in patients with 
stages IIIA and IIIB NSCLC. Benefit was also 
observed irrespective of PD-L1 status. Half the 
patients enrolled in this study had squamous-
cell lung cancer, in which the correlation between 
the PD-L1 biomarker and benefit in advanced-
stage NSCLC is weak.8 Currently, the data sup-
port treatment with consolidation in unselected 
patients. Chemotherapy and radiation therapy 
can promote immunogenic cell death of tumor 
cells by activating dendritic cells and enhancing 
antigen presentation, resulting in induction of 
adaptive immune responses. These data support 
the concept of sequencing chemoradiotherapy 
before blockade of the programmed death 1 path-
way. Refinement of this combined strategy regard-
ing the timing and duration of checkpoint-inhib-
itor intervention will require further evaluation.
Immune checkpoint blockade is currently be-
ing evaluated in multiple ongoing clinical trials 
of neoadjuvant immune checkpoint-blockade ap-
proaches in patients with early-stage NSCLC. 
Blood-based next-generation sequencing of tumor 
DNA may allow investigators to prospectively 
identify patients with resectable stage I to III 
NSCLC who are at the greatest risk for relapse. 
In a recent study, after resection of NSCLC, at 
least two detectable single-nucleotide variants 
were identified preoperatively in 13 of 14 pa-
tients with relapse.9 The data from the PACIFIC 
study provide support for the integration of 
immune checkpoint blockade for unresectable 
stage III NSCLC and will undoubtedly shape the 
design of future trials in stage I to III NSCLC.
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
Julie R. Ingelfinger, M.D.
Approximately half the patients with autosomal 
dominant polycystic kidney disease (ADPKD), a 
condition due to deficiency in polycystin 1 or 2, 
have end-stage kidney disease by 60 years of 
age.1,2 Once progression begins, the mean de-
cline in the estimated glomerular filtration rate 
(GFR) is approximately 4 to 6 ml per minute per 
1.73 m2 of body-surface area per year.
Therapy to prevent deterioration of GFR in 
patients with ADPKD has been elusive, despite 
mechanistic studies targeting pathogenesis. In 
addition, the burden of therapy in patients who 
have other symptoms from their ADPKD — hy-
pertension, abdominal fullness and pain from 
cysts, hematuria, urinary tract infections, and 
nephrolithiasis, for example — is substantial.3
The value of various dietary changes (high 
water intake, low-salt diet, and soy diet) has 
been investigated, but these changes have limit-
ed efficacy. As more is learned about aberrant 
polycystin trafficking and signaling and other 
contributors to disease progression, targeted 
therapy is becoming feasible.4 Medications that 
have been evaluated include renoprotective agents, 
such as angiotensin-converting–enzyme inhibi-
tors and angiotensin-receptor blockers; drugs 
that specifically interfere with pathways involved 
in the growth of kidney cysts, such as vasopressin-
receptor antagonists, somatostatin, and interrupt-
ers of the mechanistic target of rapamycin 
(mTOR) pathway; and cytokine blockers. To date, 
studies of medications that inhibit the effects of 
vasopressin have been particularly encouraging.
Laboratory studies have shown that relatively 
high levels of cyclic adenosine monophosphate 
(cAMP) facilitate cystogenesis in patients with 
ADPKD.5 Vasopressin V2-receptor antagonists de-
crease cAMP within cells and slow the decline in 
kidney function in animal models.2 Early clini-
cal studies were encouraging, and a multicenter, 
placebo-controlled, double-blind trial (the Tolvap-
tan Efficacy and Safety in Management of Auto-
somal Dominant Polycystic Kidney Disease and 
Its Outcomes [TEMPO] 3:4 trial)6 showed that in 
patients with an estimated GFR of more than 60 
ml per minute per 1.73 m2, tolvaptan slowed the 
rate of kidney growth (the primary outcome); it 
also slowed the decline in the estimated GFR. 
However, more participants in the tolvaptan 
group than in the placebo group discontinued 
the medication owing to adverse events (23% vs. 
14%; events were most often related to polyuria, 
polydipsia, nocturia, and urinary frequency). Fur-
thermore, tolvaptan led to more instances of in-
creased liver-enzyme levels, although abnormali-
ties resolved after the discontinuation of the drug. 
After the publication of the results of the TEMPO 
3:4 trial, the European Medicines Agency and 
the Health Products and Food Branch of Health 
Canada approved tolvaptan for the prevention of 
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